Skip to main content
TipRanks
Go Ultimate75% OFF

Waters (WAZ) AI Stock Analysis

0 Followers
CH:WAZ

Waters

(BX Swiss:WAZ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Installed-Base RevenueWaters combines higher-value instrument sales with repeat consumables, service contracts and software revenue. Once customers standardize workflows on its platforms, ongoing utilization can support repeat purchasing and create a more durable revenue base than equipment sales alone.
Negative Factors
Sharp TTM Margin CompressionThe latest profitability reset materially weakens current earnings quality despite strong revenue growth. If low margins persist, Waters may have less operating leverage, reduced returns on its expanded asset base and less flexibility to absorb integration costs or invest for growth.

Waters (WAZ) vs. iShares MSCI Switzerland ETF (EWL)

-5%0%5%10%15%20%CH:WAZ+15.45%EWL+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 45.24B
Dividend Yield
―
Average Volume (3M)
3
Price to Earnings (P/E)
195.9
Beta (1Y)
0.16
Revenue Growth
69.55%
EPS Growth
-79.44%
Country
Switzerland
Employees
15,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Waters Business Overview & Revenue Model

Company Description

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactu...

Waters Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:7.31%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call was strongly positive. Highlights significantly outweighed the challenges, with double-digit organic growth, a 21% adjusted EPS increase, raised full-year revenue and EPS guidance, improving acquired-business execution, strong product and AI momentum, cost-savings progress and a constructive 2027 framework. The main negatives were limited reported growth in the acquired businesses, China DRG and channel-inventory headwinds, constrained free cash flow, elevated inventory and acquisition-related costs.

Positive Updates

Strong Third-Quarter Revenue and EPS Growth
Total company as-reported revenue was $1.767 billion, including $871 million of organic revenue and $896 million from Waters Bioscience and Waters Diagnostic Solutions. Organic revenue grew 9% as reported and 10% in constant currency, while adjusted EPS increased 21% to $4.10, $0.05 above the high end of guidance.

Negative Updates

Acquired Businesses Delivered Limited Reported Growth
Biosciences and Diagnostic Solutions generated $896 million of third-quarter revenue, representing only 1% reported growth year over year. Diagnostic Solutions was flat on a reported basis, as expected.

Company Guidance

For 2026, organic constant currency revenue growth guidance was raised 140 basis points at the midpoint to 9.1% to 9.7%, with organic reported revenue expected at $3.429 billion to $3.447 billion; Biosciences and Diagnostic Solutions revenue is expected to be approximately $3.05 billion, a $5 million raise, and total reported revenue is expected to be approximately $6.479 billion to $6.497 billion, a $43 million raise at the midpoint. Full year adjusted EBIT margin is expected to be 28.2%, net interest expense $196 million, the tax rate 15.4%, and adjusted earnings per fully diluted share $14.60 to $14.70, representing year-over-year growth of 11% to 12% and 13% to 14% in constant currency. Fourth quarter organic constant currency revenue growth is expected to be 7% to 9%, organic reported revenue $984 million to $1.002 billion, Biosciences and Diagnostic Solutions revenue approximately $817 million, total reported revenue $1.801 billion to $1.819 billion, and adjusted earnings per fully diluted share $4.58 to $4.68; on a days adjusted basis, guidance reflects 9% to 11% organic growth and approximately 10% reported growth for acquired businesses. For 2027, the starting assumption is legacy Waters growing high single digits and legacy BD growing mid-single digits, combining to mid-single-digit plus organic growth, with a critical path to a high single-digit growth potential for the combined company, 100 basis points of adjusted operating margin expansion to 29.2%, low teens adjusted EPS growth, and mid-teens as the upside case; revenue synergies are underwritten at another $60 million added in 2027 over and above the $50 million in 2026.

Waters Risk Analysis

Waters disclosed 2 risk factors in its most recent earnings report. Waters reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.Item 1: Legal ProceedingsQ3, 2025

Waters Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:WAZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AA78Outperform$49.04B34.1820.47%0.59%8.60%19.07%
TMOTMO77Outperform$259.44B36.8713.31%0.26%8.27%9.59%
MTDMTD75Outperform$34.59B37.599999.00%―6.51%15.03%
RVTYRVTY74Outperform$17.24B68.313.50%0.18%4.56%13.22%
DHRDHR73Outperform$163.94B38.088.18%0.65%5.52%25.53%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%CH:WAZADHRMTDRVTYTMODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:WAZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:WAZWaters Corp397.2653.1615.45%
AAgilent Technologies173.9630.5221.27%
DHRDanaher Corporation233.0214.206.49%
MTDMettler-toledo International1738.91349.9525.20%
RVTYRevvity, Inc.154.3963.5569.97%
TMOThermo Fisher Scientific700.22135.0523.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.